Lilly’s Neutralizing Antibodies Reduce Risk Of Serious COVID-19 Outcomes By 70%
The bamlanivimab/etesevimab combo, filed for US emergency authorization in November, shows ability to reduce risk of hospitalization or death in COVID-19 patients. Lilly also sees prevention role for bamlanivimab.
You may also be interested in...
After disappointing initially, Lilly and Regeneron are back with compelling data for their monoclonal antibody products, but still face challenges from new COVID-19 variants and medical skepticism.
The European Medicines Agency's special review process that was used to help EU member states issue emergency use approvals for dexamethasone in COVID-19 patients is now being applied to two antibody combinations from Regeneron/Roche and Lilly.
Neutralizing antibody bamlanivimab brought in $871m during the fourth quarter, skewing already solid growth upwards. Discussion of donanemab in Alzheimer’s dominated Lilly’s quarterly call.